Related references
Note: Only part of the references are listed.MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab
S. Elhadad et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2021)
Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications
Shruti Chaturvedi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)
Complement in sickle cell disease and targeted therapy: I know one thing, that I know nothing
Athina Tampaki et al.
BLOOD REVIEWS (2021)
Genetic justification of severe COVID-19 using a rigorous algorithm
Eleni Gavriilaki et al.
CLINICAL IMMUNOLOGY (2021)
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Peter Hillmen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Sutimlimab in Cold Agglutinin Disease
Alexander Roeth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial
Antonio M. Risitano et al.
LANCET HAEMATOLOGY (2021)
Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study
Pierre-Edouard Debureaux et al.
BONE MARROW TRANSPLANTATION (2021)
Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria
Antonio M. Risitano et al.
HAEMATOLOGICA (2021)
The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria
Alexander Roeth et al.
BLOOD (2020)
Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS
Shruti Chaturvedi et al.
BLOOD (2020)
Pretransplant Genetic Susceptibility: Clinical Relevance in Transplant-Associated Thrombotic Microangiopathy
Eleni Gavriilaki et al.
THROMBOSIS AND HAEMOSTASIS (2020)
Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily
Eleni Gavriilaki et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Complementopathies and precision medicine
Eleni Gavriilaki et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases
Cynthia Magro et al.
TRANSLATIONAL RESEARCH (2020)
The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
Sara Mastaglio et al.
CLINICAL IMMUNOLOGY (2020)
Anti-C5 antibody treatment for delayed hemolytic transfusion reactions in sickle cell disease
Aline Floch et al.
HAEMATOLOGICA (2020)
A New Era in Endothelial Injury Syndromes: Toxicity of CAR-T Cells and the Role of Immunity
Eleni Gavriilaki et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
C3inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab
Carlos de Castro et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis
Panagiotis Skendros et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Interim Results of the Phase 3 Cardinal Study Long-Term Follow-up
Alexander Roth et al.
BLOOD (2020)
Long-Term Safety and Efficacy of Sutimlimab in Patients with Chronic Immune Thrombocytopenia
Catherine M. Broome et al.
BLOOD (2020)
American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support
Stella T. Chou et al.
BLOOD ADVANCES (2020)
More than one pathway: novel treatment for ITP
Cindy E. Neunert et al.
BLOOD (2019)
Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis
Gerard Socie et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Small-molecule factor B inhibitor for the treatment of complement-mediated diseases
Anna Schubart et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Clinical promise of next-generation complement therapeutics
Dimitrios C. Mastellos et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Linking Complement Activation, Coagulation, and Neutrophils in Transplant-Associated Thrombotic Microangiopathy
Eleni Gavriilaki et al.
THROMBOSIS AND HAEMOSTASIS (2019)
Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT
Antonio M. Risitano et al.
FRONTIERS IN IMMUNOLOGY (2019)
The Human Platelet as an Innate Immune Cell: Interactions Between Activated Platelets and the Complement System
Oskar Eriksson et al.
FRONTIERS IN IMMUNOLOGY (2019)
Complement Component C5 and TLR Molecule CD14 Mediate Heme-Induced Thromboinflammation in Human Blood
Anub M. Thomas et al.
JOURNAL OF IMMUNOLOGY (2019)
A Phase 2 Open-Label Study of Danicopan (ACH-0144471) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy
Austin Kulasekararaj et al.
BLOOD (2019)
Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial
Ulrich Jaeger et al.
BLOOD (2019)
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study
Austin G. Kulasekararaj et al.
BLOOD (2019)
Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study
Jong Wook Lee et al.
BLOOD (2019)
Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics
Eleni Gavriilaki et al.
FRONTIERS IN IMMUNOLOGY (2019)
Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria
Antonio M. Risitano et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Contribution of alternative complement pathway to delayed hemolytic transfusion reaction in sickle cell disease
Satheesh Chonat et al.
HAEMATOLOGICA (2018)
Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action
Douglas Sheridan et al.
PLOS ONE (2018)
C1q restrains autoimmunity and viral infection by regulating CD8+ T cell metabolism
Guang Sheng Ling et al.
SCIENCE (2018)
Contribution of alternative complement pathway to delayed hemolytic transfusion reaction in sickle cell disease
Satheesh Chonat et al.
HAEMATOLOGICA (2018)
Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition
Efthymia Vlachaki et al.
HEMOGLOBIN (2018)
Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome
Xuan Yuan et al.
HAEMATOLOGICA (2017)
Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome
Xuan Yuan et al.
HAEMATOLOGICA (2017)
Paroxysmal nocturnal haemoglobinuria
Anita Hill et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases
Taku Fukuzawa et al.
SCIENTIFIC REPORTS (2017)
Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation: A Comparison of Eculizumab Therapy and Conventional Therapy
Stephan R. Bohl et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Transplant-associated thrombotic microangiopathy: opening Pandora's box
E. Gavriilaki et al.
BONE MARROW TRANSPLANTATION (2017)
Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD
Nicholas J. Gloude et al.
BLOOD (2017)
Use of the complement inhibitor Coversin to treat HSCT-associated TMA
Timothy H. J. Goodship et al.
BLOOD ADVANCES (2017)
The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy
Sonata Jodele et al.
BLOOD (2016)
Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study
Michael Loschi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination
Sonata Jodele et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients
Guillaume Dumas et al.
BLOOD (2016)
Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy
S. Vasu et al.
BONE MARROW TRANSPLANTATION (2016)
Small-molecule factor D inhibitors targeting the alternative complement pathway
Jurgen Maibaum et al.
NATURE CHEMICAL BIOLOGY (2016)
Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future
Antonio M. Risitano et al.
SEMINARS IN IMMUNOLOGY (2016)
The role of complement activation in thrombosis and hemolytic anemias
John Chapin et al.
TRANSFUSION AND APHERESIS SCIENCE (2016)
Plasmin as a complement C5 convertase
Lawrence L. Leung et al.
EBIOMEDICINE (2016)
A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement-Mediated Diseases: Preliminary Phase 1/2 Study Results in Patients with PNH
Anita Hill et al.
BLOOD (2016)
Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria
Zhuoer Lin et al.
BLOOD (2015)
Modified Ham test for atypical hemolytic uremic syndrome
Eleni Gavriilaki et al.
BLOOD (2015)
Complement An Overview for the Clinician
Juan Carlos Varela et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2015)
Current and Future Pharmacologic Complement Inhibitors
Antonio M. Risitano
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2015)
Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab
Mark Boonyasampant et al.
TRANSFUSION (2015)
Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC
Flore Sicre de Fontbrune et al.
TRANSPLANTATION (2015)
Platelets and the complement cascade in atherosclerosis
Johannes Patzelt et al.
FRONTIERS IN PHYSIOLOGY (2015)
Safety and Pharmacokinetics of the Complement Inhibitor TT30 in a Phase I Trial for Untreated PNH Patients
Antonio M. Risitano et al.
BLOOD (2015)
Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria
Antonio M. Risitano et al.
BLOOD (2014)
Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults
Sonata Jodele et al.
BLOOD (2014)
TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins
Ju Shi et al.
BLOOD (2014)
Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma
Ulla Randen et al.
HAEMATOLOGICA (2014)
Genetic Variants in C5 and Poor Response to Eculizumab
Jun-ichi Nishimura et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria
Peter Hillmen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Rational Engineering of a Minimized Immune Inhibitor with Unique Triple-Targeting Properties
Christoph Q. Schmidt et al.
JOURNAL OF IMMUNOLOGY (2013)
Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway
Michael J. Krisinger et al.
BLOOD (2012)
The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment
Antonio M. Risitano et al.
BLOOD (2012)
Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP)
Abderrahim Najaoui et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders
Antonio M. Risitano
IMMUNOBIOLOGY (2012)
Peptide and protein inhibitors targeting the C3 convertase efficiently prevent surface C3 deposition and subsequent hemolysis of paroxysmal nocturnal hemoglobinuria (PNH) erythrocytes
Antonio M. Risitano et al.
IMMUNOBIOLOGY (2012)
Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival
Richard J. Kelly et al.
BLOOD (2011)
Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib
Kenneth R. Carson et al.
BLOOD (2010)
Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura
Ellinor I. B. Peerschke et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Paroxysmal nocturnal hemoglobinuria and eculizumab
Lucio Luzzatto et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Molecular Intercommunication between the Complement and Coagulation Systems
Umme Amara et al.
JOURNAL OF IMMUNOLOGY (2010)
Paroxysmal Nocturnal Hemoglobinuria -- Hemolysis before and after Eculizumab.
Antonio M. Risitano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab
Antonio M. Risitano et al.
BLOOD (2009)
Posttransplant thrombotic microangiopathy: sensitivity of proposed new diagnostic criteria
Glen A. Kennedy et al.
TRANSFUSION (2009)
Paroxysmal nocturnal hemoglobinuria:: natural history of disease subcategories
Regis Peffault de Latour et al.
BLOOD (2008)
Evidence for non-traditional activation of complement factor C3 during murine liver regeneration
Amelia Clark et al.
MOLECULAR IMMUNOLOGY (2008)
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
Robert A. Brodsky et al.
BLOOD (2008)
Harmful molecular mechanisms in sepsis
Daniel Rittirsch et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria
Peter Hillmen et al.
BLOOD (2007)
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
Russell P. Rother et al.
NATURE BIOTECHNOLOGY (2007)
Complement-targeted therapeutics
Daniel Ricklin et al.
NATURE BIOTECHNOLOGY (2007)
Simultaneous Activation of Complement and Coagulation by MBL-Associated Serine Protease 2
Anders Krarup et al.
PLOS ONE (2007)
A novel c5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways
Konstantinos Ritis et al.
JOURNAL OF IMMUNOLOGY (2006)
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria
Peter Hillmen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin
Madan Katragadda et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Generation of C5a in the absence of C3: a new complement activation pathway
Markus Huber-Lang et al.
NATURE MEDICINE (2006)
The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin - A novel mechanism of human disease
RP Rother et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients
S Berentsen et al.
BLOOD (2004)
Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria
P Hillmen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Complement activation in factor D-deficient mice
YY Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Advances in immunology: Complement (First of two parts).
MJ Walport
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
